Evaluation of the Effects of Neurexan® on Short-Term Insomnia, Daytime Performance and Stress Response by Polysomnography (PSG), Electroencephalogram (EEG), Stress Biomarkers and Patient-Reported Outcomes (PROs) An Exploratory, Placebo-Controlled Trial in Short-Term Insomnia Patients

You likely can't join if

• 1. Patients with insomnia symptoms present longer than 90 days prior to Screening Visit 2. Based on the diagnostic interview, reported history (within 2 years) of other sleep disorders (e.g., chronic insomnia, circadian rhythm sleep disorders, restless legs syndrome (RLS), obstructive sleep apnea (OSA)), i.e., STOPBang (SBQ) questionnaire score ≥5, International Restless Legs Scale score ≥16) 3. Based on the first polysomnographic screening night at Baseline 1, insomnia due to sleep apnea or periodic limb movement disorder (PLMD): OSA (Apnea Hypopnea Index of >5 events/ hour), PLMD (Periodic Limb Movement Index (PLMI) >15 events/ hour) 4. Rotating shift work with overnight shifts 5. History of psychiatric disorders within the last 6 months prior to Screening Visit according to the Structured Clinical Interview for DSM-5® Disorders – Clinician Version (SCID-5-CV) 6. History of sensitivity to any component of Neurexan® 7. Unwilling or unable to comply with all the requirements of the clinical trial protocol 8. Cognitive impairment (cut-off of 24 points in the Montreal Cognitive Assessment [MoCA]; Thomann, Berres et al. 2020) at Screening Visit 9. Any history of or current abuse of alcohol and/or amphetamines, benzodiazepines, cocaine, marijuana, methaqualone, methadone, opioids, propoxyphene, barbiturates, phencyclidine; or expected to take during trial participation (urine drug screening at Screening Visit and adaptation nights) 10. Current use of medication affecting sleep, i.e., antidepressants, antipsychotics, diuretics, blood pressure drugs, anti-dementia drugs (e.g., piracetam), herbal and homeopathic medicine, hormone preparations (e.g., thyroxine) with the exception of hormonal contraceptives 11. Use of Neurexan® within the last two weeks from Screening Visit 12. Non-pharmacological insomnia therapies (e.g., cognitive behavioral therapy within the last 6 months of Screening Visit, sleep restriction therapy, complementary and alternative therapies as meditation, Traditional Chinese Medicine, aromatherapy) 13. Excessive consumption of xanthine-containing beverages (more than 7 cups daily of coffee or tea or other beverages containing xanthines) 14. Use of nicotine during the last 6 months prior to Screening Visit 15. Participation in any interventional clinical study within the past 30 days prior to Screening Visit 16. Any relationship of dependence with the Sponsor or with the Investigator 17. Active infection/ disease (C-Reactive Protein [CRP] >5 mg/l) 18. Hypertension defined as systolic blood pressure ≥140 mmHg (Burnier, 2018) 19. History of neurological, rheumatic, chronic pain, immune, cardiovascular, pulmonary, liver/ kidney, or metabolic disorder within the last 6 months prior to Screening Visit 20. Nocturia 21. Pregnancy (as proven by positive urine pregnancy test at Screening Visit) or breastfeeding 22. Patients with moderate to severe skin allergies and/or eczema 23. Raynaud's disease 24. Donation of blood or platelets 3 months prior to or in-between in-hospital visits.